Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (VizTM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005086/en/
Viz.ai Announces Agreement with Bristol Myers Squibb on Hypertrophic Cardiomyopathy (Graphic: Business Wire)
“HCM is the most common inherited heart disease with an estimated prevalence between 1 in 200 and 1 in 500, and one of the leading causes of sudden cardiac death in people under age 35,” said David Huneycutt, M.D., F.A.C.C., a cardiologist at HCA Healthcare’s TriStar Centennial Medical Center in Nashville, Tenn. and an enterprise-wide cardiovascular physician director. “Since a high percentage of patients remain undiagnosed, it is critical that we find solutions to identify patients with suspected HCM sooner.”
HCM is defined by thickened heart muscle, which can make it harder for the heart to pump blood. It is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure. HCM is estimated to impact an estimated 750,000 people in the United States and 20 million worldwide.1
“At BMS, we believe that the use of AI to detect key, subtle characteristics in bio signals to aid physicians in the screening, diagnosis, treatment and monitoring of diseases will have a critical and positive impact on patients’ lives,” said Suhas Krishna, Vice President, Head of Digital Health Product Management, Bristol Myers Squibb. “We are excited to continue building momentum in our support of Viz.ai’s research and development program. The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”
Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care. Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals, which is expected to advance cardiac care coordination through a mobile-based electrocardiogram viewer, built with timely AI-powered alerts and communication tools. The Viz.ai Intelligent Care Coordination Platform, which includes Viz.ai Cardio Suite, is adopted by nearly 1,300 hospitals in the U.S. Viz.ai has placed Viz HCM at several hospitals, including select HCA Healthcare facilities, under research agreements to further evaluate the product in clinical practice. The company plans to launch Viz HCM broadly upon FDA clearance.
“Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time,” said Dr. Chris Mansi, CEO at Viz.ai. “Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”
For more information on Viz HCM for research, please visit https://www.viz.ai/research/hcm.
*Viz HCM not available for sale. Investigational use only
1 Maron BJ. N Engl J Med. 2018; 379:655-68.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and helps improve outcomes. Backed by real-world clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005086/en/
Contact information
Ariane Lovell
ariane.lovell@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D18.11.2025 14:55:00 EET | Press release
In the United Arab Emirates, where cities like Abu Dhabi and Dubai consistently rank among the world's most forward-thinking, the Emirate of Sharjah, the country's cultural and knowledge capital, has decisively positioned itself as a premier hub for research and innovations in healthcare. This transformation is primarily driven by the Sharjah Research, Technology and Innovation Park (SPARK) formerly SRTIP, SRTI Park. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118121763/en/ SPARK Headquarters (SPARK HQ) (Photo: AETOSWire) This ambition was powerfully demonstrated during the recent "Sharjah Next: Healthcare" forum, which transcended a typical conference, evolving into a powerful statement of intent. It assembled a host of global healthcare luminaries, including Professor Sir Magdi Yacoub, a pioneer in cardiothoracic surgery; Professor Humaid Obaid Al-Shamsi, a leading Emirati oncologist; and Dr. Vladimir Ivkovic of Harv
Options Selects atNorth Data Center for Private AI Solution18.11.2025 14:14:00 EET | Press release
Options Technology (Options), the leading provider of capital markets infrastructure, today announced a partnership with atNorth, the leading Nordic high-density colocation and built-to-suit datacenter provider, to host its expanded private AI solution, at atNorth’s ICE02 data center in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118956675/en/ Options Selects atNorth Data Center for Private AI Solution Options infrastructure expansion results from increasing demand from financial firms, such as hedge funds, investment banks, and proprietary trading firms, for high-density computing power, driven by the rapid adoption of AI for trading strategies, risk management, and data analytics. The business aims to address a gap in the market for private cloud infrastructure specifically tailored to the requirements of the financial services industry. Recognizing the need for a secure, sustainable, AI ready and cost-effec
Loyalty Upgraded: Hilton Honors Introduces Faster Path to Elite Status and Reveals New Premium Tier – Diamond Reserve18.11.2025 14:02:00 EET | Press release
Committed to rewarding loyalty at every stage of the travel journey, today Hilton (NYSE: HLT) announced exciting changes to its award-winning Hilton Honors loyalty program. Debuting this January, Hilton will introduce its most elite tier yet – Diamond Reserve – with new elevated benefits, including a Confirmable Upgrade Reward that can be instantly redeemed at the time of booking, guaranteed 4 p.m. late checkout, and exclusive customer service support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118002486/en/ (Photo: Hilton) Committed to rewarding loyalty at every stage of the travel journey, Hilton announced exciting changes to its award-winning Hilton Honors loyalty program. (Waldorf Astoria New York) What’s more, Hilton Honors Gold status will become the most valuable mid-tier status, with members still enjoying all the current benefits of Gold status, including space-available room upgrades and on-property Food & B
NIQ Launches New Brand Traction Score Designed to Reveal How Effectively FMCG Brands Convert Shelf Presence Into Real Consumer Purchases18.11.2025 13:45:00 EET | Press release
Coca-Cola has been recognised as the top FMCG brand in Western Europe for its success in driving conversions, according to NielsenIQ (NIQ)’s Brand Traction Score, a new metric that measures how effectively brands convert their shelf presence into actual consumer purchases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118769598/en/ NIQ Brand Traction Score The NIQ Brand Traction Score combines two of NIQ’s most powerful data sources: insights from its Consumer Panel, which tracks how frequently shoppers buy a brand, and its Retail Measurement data, which captures how widely and deeply that brand is distributed across stores. This strategy saw some of the top-performing brands grow by 40% due to expanding their presence, with more than 60% of their unit growth coming from households adding these brands to their category repertoire. There was also growth (18%) from existing buyers expanding their brand and category purchas
Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide18.11.2025 13:37:00 EET | Press release
How can we bring the excellence of Italian culinary tradition into the future? How can we transform everyday products into experiences that surprise the senses, create emotions, and accompany people in moments of pleasure, sharing, and discovery? The answer for Barilla Group is the Barilla Innovation & Technology Experience (BITE) in Parma, marking the company’s most significant investment in food innovation in recent years. With almost 14,000m², more than €20 million invested and an additional €2 million per year dedicated to equipment upgrades, BITE stands as a global hub designed to foster development across the Group’s portfolio. Pasta, sauces, and bakery become a territory of exploration here, where research and technology serve Barilla's passion for good food. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118376430/en/ Guido, Paolo and Luca Barilla. © Barilla Rooted in an approach of collaboration with leading inte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom